论文部分内容阅读
目的：探讨自体外周血造血干细胞移植（ＡＢＳＣＴ）治疗恶性血液病的疗效。方法：ＡＢＳＣＴ１３例，自体外周血干细胞（ＰＢＳＣ）及自体骨髓联合移植１５例。移植前采用化疗加多抗甲素或粒细胞集落刺激因子（ＧＣＳＦ）动员外周血干细胞。结果：多抗甲素组每例采集单个核细胞数为（３．５８±２．１２）×１０８／ｋｇ，ＧＣＳＦ组为（６．６８±５．３１）×１０８／ｋｇ；接受移植的２８例患者中２１例呈持续缓解状态（ＣＣＲ），中位ＣＣＲ时间为１８（５～５８）个月，复发７例；３年无病生存率为６８．７％，复发率为２２．３％。结论：两种动员方案均有良好的动员效果；ＡＢＳＣＴ及ＰＢＳＣ和自体骨髓联合移植均具有良好疗效及造血功能恢复快、合并症少等优点，值得进一步推广应用。
Objective: To investigate the efficacy of autologous peripheral blood stem cell transplantation (ABSCT) in the treatment of hematological malignancies. Methods: 13 cases of ABSCT, autologous peripheral blood stem cells (PBSC) and autogenous bone marrow transplantation in 15 cases. Prior to transplantation, peripheral blood stem cells were mobilized with chemotherapy plus polyclonal anti-A or granulocyte colony-stimulating factor (G-CSF). Results: The number of mononuclear cells was (3.58±2.12)×108/kg in each case of the multi-resistant group A, and (6.68±5.31)×108/kg in the GCSF group; Of the 28 patients, 21 showed sustained remission (CCR), median CCR was 18 (5 to 58) months, and 7 relapses. The 3-year disease-free survival rate was 68.7%. The recurrence rate was 22. 3%. Conclusion: Both mobilization programs have good mobilization effects; ABSCT and PBSC combined with autologous bone marrow transplantation have good curative effect and quick recovery of hematopoietic function and fewer complications, and are worthy of further promotion and application.